The efficacy test of KTT002

The efficacy test of KTT002 - The efficacy test of KTT002

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000031053

Enrollment

345

Registered

2018-01-30

Start date

2018-02-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Healthy adults

Interventions

Ingestion of active three times a day for 8 weeks. Ingestion of control three times a day for 8 weeks. Observation group

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Healthy subjects giving written informed consent.

Exclusion criteria

Exclusion criteria: 1) Subjects with a history of allergy or might be liable to allergy related to the study 2) Subjects who have serious historical disease, marked impairment, or treatment in the liver, kidney, heart, lung, gastrointestinal tract, blood, endocrine system, or metabolism system 3) The pregnant and subjects who hope to get pregnant during the exam period 4) Subjects who are ineligible due to life-style questionnaire 5) Subjects deemed inappropriate to participate in this study by the principle investigator.

Design outcomes

Primary

Measure	Time frame
Questionnaire about physical conditions and symptoms before and after 8wks sample ingestion.	—

Countries

Japan

Contacts

Public ContactKenkichi Yamamoto

Kao Corporation R&D-Development Research-Personal Health Care Products Research

yamamoto.kenkichi@kao.com03-5630-9416

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026